Serlopitant
As of the edition of 20 October 2026, Serlopitant is a small molecule: stopped in 2020; acts on TACR1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2020
- Kind
- Small molecule
- Registered trials
- 12, 3 stopped early
- Disease areas
- Skin and connective tissue; Inherited and neonatal; Immune system; Chemically induced; Injuries; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Serlopitant.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TACR1 | Substance-P receptor | P25103 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 9 | 7 | 0 | 2 |
| Phase 3 | 3 | 2 | 0 | 1 |
| All trials | 12 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Yarrow Bioscience | Lead sponsor of trials | 2006 to now |